Try our mobile app
Exhibit 99.1
Stepan Reports Second Quarter Results
Northbrook, Illinois, July 26, 2023 -- Stepan Company (NYSE: SCL) today reported:
Second Quarter Highlights
* Adjusted net income and adjusted earnings per share are non-GAAP measures which exclude deferred compensation income/expense, cash-settled stock appreciation rights (SARs) income/expense, certain environmental remediation-related costs as well as other significant and infrequent/non-recurring items. See Table II for reconciliations of non-GAAP adjusted net income and adjusted earnings per diluted share.
** EBITDA and adjusted EBITDA are non-GAAP measures. See Table VI for calculations and GAAP reconciliations of EBITDA and adjusted EBITDA.
1
First Half Highlights
“The Company's second quarter and first half of the year financial results were significantly lower than the record quarterly results in both the first and second quarters of 2022. Lower sales volume due to demand softness across most of our markets, continued inventory destocking and the backward integration of one customer associated with the low 1,4 dioxane transition drove the 17% sales volume reduction in the first half of the year,” said Scott Behrens, President and Chief Executive Officer. "Specific to the second quarter, Surfactant and Polymer unit margins were only slightly lower versus the prior year due to less favorable product mix. Specialty Product unit margins were significantly lower due to high-cost inventory and pricing pressure related to increased imports of MCTs into certain market segments. Rigid Polyol volumes gradually improved throughout the quarter. Surfactant volumes were negatively impacted by unexpected destocking activity within our Agricultural business. Cash expenses were slightly lower versus prior year due to proactive headcount and discretionary expense controls implemented earlier in the year and lower accruals for incentive-based compensation.”
Financial Summary
|
Three Months Ended |
|
|
Six Months Ended |
|
||||||||||||||||||
($ in thousands, except per share data) |
2023 |
|
|
2022 |
|
|
% |
|
|
2023 |
|
|
2022 |
|
|
% |
|
||||||
Net Sales |
$ |
579,975 |
|
|
$ |
751,633 |
|
|
|
(23 |
)% |
|
$ |
1,231,411 |
|
|
$ |
1,426,909 |
|
|
|
(14 |
)% |
Operating Income |
$ |
17,809 |
|
|
$ |
77,640 |
|
|
|
(77 |
)% |
|
$ |
38,866 |
|
|
$ |
140,986 |
|
|
|
(72 |
)% |
Net Income |
$ |
12,684 |
|
|
$ |
52,126 |
|
|
|
(76 |
)% |
|
$ |
28,826 |
|
|
$ |
96,935 |
|
|
|
(70 |
)% |
Earnings per Diluted Share |
$ |
0.55 |
|
|
$ |
2.26 |
|
|
|
(76 |
)% |
|
$ |
1.25 |
|
|
$ |
4.19 |
|
|
|
(70 |
)% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||
Adjusted Net Income * |
$ |
12,057 |
|
|
$ |
53,009 |
|
|
|
(77 |
)% |
|
$ |
28,476 |
|
|
$ |
93,736 |
|
|
|
(70 |
)% |
Adjusted Earnings per Diluted Share * |
$ |
0.53 |
|
|
$ |
2.30 |
|
|
|
(77 |
)% |
|
$ |
1.24 |
|
|
$ |
4.05 |
|
|
|
(69 |
)% |
* See Table II for reconciliations of non-GAAP adjusted net income and earnings per diluted share. |
|
Summary of Second Quarter Adjusted Net Income Items
Adjusted net income excludes non-operational deferred compensation income/expense, cash-settled SARs income/expense, certain environmental remediation costs and other significant and infrequent or non-recurring items.
2
Percentage Change in Net Sales
Net sales in the second quarter of 2023 decreased 23% year-over-year primarily due to a 19% decrease in global sales volume. Lower selling prices negatively impacted net sales by 4% and largely reflect less favorable product mix and competitive pressures.
|
|
Three Months Ended |
|
|
Six Months Ended |
|
||
Volume |
|
|
(19 |
)% |
|
|
(17 |
)% |
Selling Price & Mix |
|
|
(4 |
)% |
|
|
4 |
% |
Foreign Translation |
|
|
0 |
% |
|
|
(1 |
)% |
Total |
|
|
(23 |
)% |
|
|
(14 |
)% |
Segment Results
|
|
Three Months Ended |
|
|
Six Months Ended |
|
||||||||||||||||||
($ in thousands) |
|
2023 |
|
|
2022 |
|
|
% |
|
|
2023 |
|
|
2022 |
|
|
% |
|
||||||
Net Sales |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||
Surfactants |
|
$ |
391,686 |
|
|
$ |
485,084 |
|
|
|
(19 |
)% |
|
$ |
859,514 |
|
|
$ |
953,350 |
|
|
|
(10 |
)% |
Polymers |
|
$ |
164,515 |
|
|
$ |
238,885 |
|
|
|
(31 |
)% |
|
$ |
325,642 |
|
|
$ |
425,964 |
|
|
|
(24 |
)% |
Specialty Products |
|
$ |
23,774 |
|
|
$ |
27,664 |
|
|
|
(14 |
)% |
|
$ |
46,255 |
|
|
$ |
47,595 |
|
|
|
(3 |
)% |
Total Net Sales |
|
$ |
579,975 |
|
|
$ |
751,633 |
|
|
|
(23 |
)% |
|
$ |
1,231,411 |
|
|
$ |
1,426,909 |
|
|
|
(14 |
)% |
|
|
Three Months Ended |
|
|
Six Months Ended |
|
||||||||||||||||||
($ in thousands) |
|
2023 |
|
|
2022 |
|
|
% |
|
|
2023 |
|
|
2022 |
|
|
% |
|
||||||
Operating Income |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||
Surfactants |
|
$ |
15,140 |
|
|
$ |
48,249 |
|
|
|
(69 |
)% |
|
$ |
42,196 |
|
|
$ |
102,018 |
|
|
|
(59 |
)% |
Polymers |
|
$ |
16,321 |
|
|
$ |
33,912 |
|
|
|
(52 |
)% |
|
$ |
26,325 |
|
|
$ |
48,041 |
|
|
|
(45 |
)% |
Specialty Products |
|
$ |
3,773 |
|
|
$ |
9,866 |
|
|
|
(62 |
)% |
|
$ |
6,302 |
|
|
$ |
13,561 |
|
|
|
(54 |
)% |
Total Segment Operating Income |
|
$ |
35,234 |
|
|
$ |
92,027 |
|
|
|
(62 |
)% |
|
$ |
74,823 |
|
|
$ |
163,620 |
|
|
|
(54 |
)% |
Corporate Expenses |
|
$ |
(17,425 |
) |
|
$ |
(14,387 |
) |
|
|
21 |
% |
|
$ |
(35,957 |
) |
|
$ |
(22,634 |
) |
|
|
59 |
% |
Consolidated Operating Income |
|
$ |
17,809 |
|
|
$ |
77,640 |
|
|
|
(77 |
)% |
|
$ |
38,866 |
|
|
$ |
140,986 |
|
|
|
(72 |
)% |
3
Total segment operating income for the second quarter of 2023 decreased $56.8 million, or 62%, versus the prior year quarter. Total segment operating income in the first half of 2023 was down $88.8 million, or 54%, versus the prior year.
4
|
|
Three Months Ended |
|
|
% |
|
|
Six Months Ended |
|
|
% |
|
||||||||||||
($ in millions) |
|
2023 |
|
|
2022 |
|
|
|
|
|
2023 |
|
|
2022 |
|
|
|
|
||||||
EBITDA |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||
Surfactants |
|
$ |
31.1 |
|
|
$ |
61.6 |
|
|
|
(50 |
)% |
|
$ |
73.5 |
|
|
$ |
128.6 |
|
|
|
(43 |
)% |
Polymers |
|
$ |
24.6 |
|
|
$ |
41.8 |
|
|
|
(41 |
)% |
|
$ |
42.9 |
|
|
$ |
63.6 |
|
|
|
(33 |
)% |
Specialty Products |
|
$ |
5.2 |
|
|
$ |
11.4 |
|
|
|
(54 |
)% |
|
$ |
9.1 |
|
|
$ |
16.5 |
|
|
|
(45 |
)% |
Unallocated Corporate |
|
$ |
(14.2 |
) |
|
$ |
(19.3 |
) |
|
|
(26 |
)% |
|
$ |
(30.6 |
) |
|
$ |
(28.5 |
) |
|
|
7 |
% |
Consolidated EBITDA |
|
$ |
46.7 |
|
|
$ |
95.5 |
|
|
|
(51 |
)% |
|
$ |
94.9 |
|
|
$ |
180.2 |
|
|
|
(47 |
)% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||
Adjusted EBITDA |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||
Surfactants |
|
$ |
31.0 |
|
|
$ |
61.7 |
|
|
|
(50 |
)% |
|
$ |
73.4 |
|
|
$ |
128.4 |
|
|
|
(43 |
)% |
Polymers |
|
$ |
24.6 |
|
|
$ |
41.8 |
|
|
|
(41 |
)% |
|
$ |
42.9 |
|
|
$ |
63.5 |
|
|
|
(32 |
)% |
Specialty Products |
|
$ |
5.2 |
|
|
$ |
11.4 |
|
|
|
(54 |
)% |
|
$ |
9.1 |
|
|
$ |
16.5 |
|
|
|
(45 |
)% |
Unallocated Corporate |
|
$ |
(15.0 |
) |
|
$ |
(18.2 |
) |
|
|
(18 |
)% |
|
$ |
(30.9 |
) |
|
$ |
(32.4 |
) |
|
|
(5 |
)% |
Consolidated Adjusted EBITDA |
|
$ |
45.8 |
|
|
$ |
96.7 |
|
|
|
(53 |
)% |
|
$ |
94.5 |
|
|
$ |
176.0 |
|
|
|
(46 |
)% |
Corporate Expenses
|
|
Three Months Ended |
|
|
Six Months Ended |
|
||||||||||||||||||
($ in thousands) |
|
2023 |
|
|
2022 |
|
|
% |
|
|
2023 |
|
|
2022 |
|
|
% |
|
||||||
Total Corporate Expenses |
|
$ |
17,424 |
|
|
$ |
14,387 |
|
|
|
21 |
% |
|
$ |
35,957 |
|
|
$ |
22,634 |
|
|
|
59 |
% |
Excluded Items: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||
Deferred Compensation |
|
$ |
(743 |
) |
|
$ |
3,406 |
|
|
NM |
|
|
$ |
(2,245 |
) |
|
$ |
10,907 |
|
|
NM |
|
||
Business Restructuring Expense |
|
$ |
(42 |
) |
|
$ |
(81 |
) |
|
|
(48 |
)% |
|
$ |
(199 |
) |
|
$ |
(133 |
) |
|
|
50 |
% |
Environmental Remediation Expense |
|
$ |
(52 |
) |
|
$ |
(327 |
) |
|
|
(84 |
)% |
|
$ |
(461 |
) |
|
$ |
(630 |
) |
|
|
(27 |
)% |
Adjusted Corporate Expenses |
|
$ |
16,587 |
|
|
$ |
17,385 |
|
|
|
(5 |
)% |
|
$ |
33,052 |
|
|
$ |
32,778 |
|
|
|
1 |
% |
* See Table III for a discussion of deferred compensation plan accounting. |
Income Taxes
The Company’s effective tax rate was 20.4% in the first half of 2023 versus 24.8% in the first half of 2022. This decrease was primarily attributable to more favorable tax benefits derived from stock-based compensation awards exercised or distributed in the first half of 2023 versus the first half of 2022.
5
Shareholder Return
The Company paid $8.2 million of dividends to shareholders in the second quarter of 2023 and $16.3 million of dividends to shareholders during the first six months of 2023. The Company has not repurchased any Company stock during the first half of 2023 and has $125.1 million remaining under the share repurchase program authorized by its Board of Directors. The Company has increased its dividend on the Company’s common stock for 55 consecutive years.
Selected Balance Sheet Information
The Company’s total debt decreased by $28.4 million and cash increased by $6.9 million versus March 31, 2023. The decrease in debt primarily reflects scheduled debt repayments in June 2023 and lower borrowings against the Company's revolving credit facility. The Company’s net debt level decreased $35.3 million versus March 31, 2023 and the net debt ratio decreased from 33% to 31% in the quarter (Net Debt and Net Debt Ratio are non-GAAP measures).
($ in millions) |
6/30/23 |
|
|
3/31/2023 |
|
|
12/31/2022 |
|
|||
Net Debt |
|
|
|
|
|
|
|
|
|||
Total Debt |
$ |
682.6 |
|
|
$ |
711.0 |
|
|
$ |
587.1 |
|
Cash |
|
133.9 |
|
|
|
127.0 |
|
|
|
173.8 |
|
Net Debt |
$ |
548.7 |
|
|
$ |
584.0 |
|
|
$ |
413.3 |
|
Equity |
|
1,215.1 |
|
|
|
1,189.9 |
|
|
|
1,166.1 |
|
Net Debt + Equity |
$ |
1,763.8 |
|
|
$ |
1,773.9 |
|
|
$ |
1,579.4 |
|
Net Debt / (Net Debt + Equity) |
|
31 |
% |
|
|
33 |
% |
|
|
26 |
% |
The major working capital components were:
($ in millions) |
6/30/23 |
|
|
3/31/23 |
|
|
12/31/22 |
|
|||
Net Receivables |
$ |
423.4 |
|
|
$ |
470.3 |
|
|
$ |
436.9 |
|
Inventories |
|
340.0 |
|
|
|
368.4 |
|
|
|
402.5 |
|
Accounts Payable |
|
(287.6 |
) |
|
|
(289.1 |
) |
|
|
(375.7 |
) |
Total |
$ |
475.8 |
|
|
$ |
549.6 |
|
|
$ |
463.7 |
|
Capital spending was $67.7 million during the quarter and $159.9 million during the first half of 2023. This compares to $69.2 million and $129.5 million, respectively, in the prior year. The first half year-over-year increase is primarily due to increased expenditures in the U.S. for the advancement of the Company’s new alkoxylation facility in Pasadena, Texas and new capability and capacity to produce ether sulfates that meet new regulatory limits on 1,4 dioxane. Capital spending in the second half of 2023 is expected to be in the range of $80 million to $90 million, down substantially versus the first six months of 2023, as spending on low 1,4 dioxane investments nears completion and lower capital outlays are anticipated for the new alkoxylation facility versus those incurred during the first half of the year. For the full year, capital expenditures are expected to be in the range of $240 million to $250 million.
Outlook
“Looking forward, we continue to believe second half of the year volume and margins will incrementally improve versus the first half of 2023, driven by the continued gradual recovery in Rigid Polyol demand, growth in Surfactant volumes associated with new
6
contracted business and sequentially lower raw material costs,” said Scott Behrens, President and Chief Executive Officer. "Further cost control and cash management initiatives are underway given the current business performance and include a voluntary early retirement program for eligible employees at our corporate headquarters and a plan to reduce inventory levels by an additional $40 million during the remainder of the year. Additionally, capital spending in the second half of the year is projected to be in the range of $80 to $90 million, down from the record $160 million spent in the first half of the year, due to the expected completion of our low 1,4 dioxane investments in the coming weeks and lower second half capital spending required to complete our Pasadena alkoxylation investment which is expected to be operational mid-year 2024. While we acknowledge the current environment has been challenging, we remain confident in our long-term strategic growth and innovation initiatives.”
Conference Call
Stepan Company will host a conference call to discuss its second quarter results at 9:00 a.m. ET (8:00 a.m. CT) on July 26, 2023. The call can be accessed by phone and webcast. To access the call by phone, please click on this Registration Link, complete the form and you will be provided with dial in details and a PIN. To avoid delays, we encourage participants to dial into the conference call ten minutes ahead of the scheduled start time. The webcast can be accessed through the Investors/Conference Calls page at www.stepan.com. A webcast replay of the conference call will be available at the same location shortly after the call.
Supporting Slides
Slides supporting this press release will be made available at www.stepan.com through the Investors/Presentations page at approximately the same time as this press release is issued.
Corporate Profile
Stepan Company is a major manufacturer of specialty and intermediate chemicals used in a broad range of industries. Stepan is a leading merchant producer of surfactants, which are the key ingredients in consumer and industrial cleaning and disinfection compounds and in agricultural and oilfield solutions. The Company is also a leading supplier of polyurethane polyols used in the expanding thermal insulation market, and CASE (Coatings, Adhesives, Sealants, and Elastomers) industries.
Headquartered in Northbrook, Illinois, Stepan utilizes a network of modern production facilities located in North and South America, Europe and Asia.
The Company's common stock is traded on the New York Stock Exchange (NYSE) under the symbol SCL. For more information about Stepan Company please visit the Company online at www.stepan.com
More information about Stepan’s sustainability program can be found on the Sustainability page at www.stepan.com
Contact: Luis E. Rojo 847-446-7500
7
Certain information in this news release consists of forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements include statements about Stepan Company’s plans, objectives, strategies, financial performance and outlook, trends, the amount and timing of future cash distributions, prospects or future events and involve known and unknown risks that are difficult to predict. As a result, Stepan Company’s actual financial results, performance, achievements or prospects may differ materially from those expressed or implied by these forward-looking statements. In some cases, you can identify forward-looking statements by the use of words such as “may,” “could,” “expect,” “intend,” “plan,” “seek,” “anticipate,” “believe,” “estimate,” “guidance,” “predict,” “potential,” “continue,” “likely,” “will,” “would,” “should,” “illustrative” and variations of these terms and similar expressions, or the negative of these terms or similar expressions. Such forward-looking statements are necessarily based upon estimates and assumptions that, while considered reasonable by Stepan Company and its management based on their knowledge and understanding of the business and industry, are inherently uncertain. These statements are not guarantees of future performance, and stockholders should not place undue reliance on forward-looking statements.
There are a number of risks, uncertainties and other important factors, many of which are beyond Stepan Company's control, that could cause actual results to differ materially from the forward-looking statements contained in this news release. Such risks, uncertainties and other important factors include, among other factors, the risks, uncertainties and factors described in Stepan Company's Form 10-K, Form 10-Q and Form 8-K reports and exhibits to those reports, and include (but are not limited to) risks and uncertainties related to accidents, unplanned production shutdowns or disruptions in manufacturing facilities; reduced demand due to customer product reformulations or new technologies; our inability to successfully develop or introduce new products; compliance with laws; our ability to identify suitable acquisition candidates and successfully complete and integrate acquisitions; global competition; volatility of raw material and energy costs and supply; disruptions in transportation or significant changes in transportation costs; downturns in certain industries and general economic downturns; international business risks, including currency exchange rate fluctuations, legal restrictions and taxes; unfavorable resolution of litigation against us; maintaining and protecting intellectual property rights; our ability to access capital markets; global political, military, security or other instability; costs related to expansion or other capital projects; interruption or breaches of information technology systems; our ability to retain executive management and key personnel; and our debt covenants.
These forward-looking statements are made only as of the date hereof, and Stepan Company undertakes no obligation to update or revise these forward-looking statements, whether as a result of new information, future events or otherwise.
* * * * *
Tables follow
8
Table I
STEPAN COMPANY
For the Three and Six Months Ended June 30, 2023 and 2022
(Unaudited – in 000's, except per share data)
|
|
Three Months Ended |
|
|
Six Months Ended |
|
||||||||||
|
|
2023 |
|
|
2022 |
|
|
2023 |
|
|
2022 |
|
||||
Net Sales |
|
$ |
579,975 |
|
|
$ |
751,633 |
|
|
$ |
1,231,411 |
|
|
$ |
1,426,909 |
|
Cost of Sales |
|
|
513,578 |
|
|
|
620,019 |
|
|
|
1,091,454 |
|
|
|
1,186,076 |
|
Gross Profit |
|
|
66,397 |
|
|
|
131,614 |
|
|
|
139,957 |
|
|
|
240,833 |
|
Operating Expenses: |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Selling |
|
|
11,109 |
|
|
|
15,552 |
|
|
|
24,176 |
|
|
|
30,829 |
|
Administrative |
|
|
22,589 |
|
|
|
24,079 |
|
|
|
45,228 |
|
|
|
45,651 |
|
Research, Development and Technical Services |
|
|
14,105 |
|
|
|
16,690 |
|
|
|
29,243 |
|
|
|
33,163 |
|
Deferred Compensation (Income) Expense |
|
|
743 |
|
|
|
(3,406 |
) |
|
|
2,245 |
|
|
|
(10,907 |
) |
|
|
|
48,546 |
|
|
|
52,915 |
|
|
|
100,892 |
|
|
|
98,736 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
Goodwill Impairment |
|
|
- |
|
|
|
978 |
|
|
|
- |
|
|
|
978 |
|
Business Restructuring |
|
|
42 |
|
|
|
81 |
|
|
|
199 |
|
|
|
133 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
Operating Income |
|
|
17,809 |
|
|
|
77,640 |
|
|
|
38,866 |
|
|
|
140,986 |
|
Other Income (Expense): |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Interest, Net |
|
|
(3,865 |
) |
|
|
(2,727 |
) |
|
|
(6,687 |
) |
|
|
(5,033 |
) |
Other, Net |
|
|
2,370 |
|
|
|
(5,369 |
) |
|
|
4,038 |
|
|
|
(7,019 |
) |
|
|
|
(1,495 |
) |
|
|
(8,096 |
) |
|
|
(2,649 |
) |
|
|
(12,052 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
Income Before Income Taxes |
|
|
16,314 |
|
|
|
69,544 |
|
|
|
36,217 |
|
|
|
128,934 |
|
Provision for Income Taxes |
|
|
3,630 |
|
|
|
17,418 |
|
|
|
7,391 |
|
|
|
31,999 |
|
Net Income |
|
|
12,684 |
|
|
|
52,126 |
|
|
|
28,826 |
|
|
|
96,935 |
|
Net Income Per Common Share |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Basic |
|
$ |
0.56 |
|
|
$ |
2.29 |
|
|
$ |
1.27 |
|
|
$ |
4.24 |
|
Diluted |
|
$ |
0.55 |
|
|
$ |
2.26 |
|
|
$ |
1.25 |
|
|
$ |
4.19 |
|
Shares Used to Compute Net Income Per Common |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Basic |
|
|
22,768 |
|
|
|
22,792 |
|
|
|
22,763 |
|
|
|
22,842 |
|
Diluted |
|
|
22,945 |
|
|
|
23,055 |
|
|
|
22,970 |
|
|
|
23,115 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
Table II
9
Reconciliation of Non-GAAP Net Income and Earnings per Diluted Share*
|
|
Three Months Ended |
|
|
Six Months Ended |
|
||||||||||||||||||||||||||
($ in thousands, except per share amounts) |
|
2023 |
|
|
EPS |
|
|
2022 |
|
|
EPS |
|
|
2023 |
|
|
EPS |
|
|
2022 |
|
|
EPS |
|
||||||||
Net Income Reported |
|
$ |
12,684 |
|
|
$ |
0.55 |
|
|
$ |
52,126 |
|
|
$ |
2.26 |
|
|
$ |
28,826 |
|
|
$ |
1.25 |
|
|
$ |
96,935 |
|
|
$ |
4.19 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||
Deferred Compensation (Income) Expense |
|
$ |
(653 |
) |
|
$ |
(0.02 |
) |
|
$ |
518 |
|
|
$ |
0.02 |
|
|
$ |
(757 |
) |
|
$ |
(0.03 |
) |
|
$ |
(3,431 |
) |
|
$ |
(0.15 |
) |
Business Restructuring Expense |
|
$ |
31 |
|
|
$ |
- |
|
|
$ |
61 |
|
|
$ |
0.01 |
|
|
$ |
146 |
|
|
$ |
0.01 |
|
|
$ |
100 |
|
|
$ |
0.01 |
|
Cash-Settled SARs (Income) Expense |
|
$ |
(44 |
) |
|
$ |
- |
|
|
$ |
55 |
|
|
$ |
- |
|
|
$ |
(84 |
) |
|
$ |
- |
|
|
$ |
(347 |
) |
|
$ |
(0.02 |
) |
Environmental Remediation Expense |
|
$ |
39 |
|
|
$ |
- |
|
|
$ |
249 |
|
|
$ |
0.01 |
|
|
$ |
345 |
|
|
$ |
0.01 |
|
|
$ |
479 |
|
|
$ |
0.02 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||
Adjusted Net Income |
|
$ |
12,057 |
|
|
$ |
0.53 |
|
|
$ |
53,009 |
|
|
$ |
2.30 |
|
|
$ |
28,476 |
|
|
$ |
1.24 |
|
|
$ |
93,736 |
|
|
$ |
4.05 |
|
* All amounts in this table are presented after-tax
The Company believes that certain measures that are not in accordance with generally accepted accounting principles (GAAP), when presented in conjunction with comparable GAAP measures, are useful for evaluating the Company’s operating performance and provide better clarity on the impact of non-operational items. Internally, the Company uses this non-GAAP information as an indicator of business performance and evaluates management’s effectiveness with specific reference to these indicators. These measures should be considered in addition to, and are neither a substitute for, nor superior to, measures of financial performance prepared in accordance with GAAP.
Reconciliation of Pre-Tax to After-Tax Adjustments
|
|
Three Months Ended |
|
|
Six Months Ended |
|
||||||||||||||||||||||||||
($ in thousands, except per share amounts) |
|
2023 |
|
|
EPS |
|
|
2022 |
|
|
EPS |
|
|
2023 |
|
|
EPS |
|
|
2022 |
|
|
EPS |
|
||||||||
Pre-Tax Adjustments |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||
Deferred Compensation (Income) Expense |
|
$ |
(871 |
) |
|
|
|
|
$ |
681 |
|
|
|
|
|
$ |
(1,009 |
) |
|
|
|
|
$ |
(4,514 |
) |
|
|
|
||||
Business Restructuring Expense |
|
$ |
42 |
|
|
|
|
|
$ |
81 |
|
|
|
|
|
$ |
199 |
|
|
|
|
|
$ |
133 |
|
|
|
|
||||
Cash-Settled SARs (Income) Expense |
|
$ |
(58 |
) |
|
|
|
|
$ |
73 |
|
|
|
|
|
$ |
(111 |
) |
|
|
|
|
$ |
(455 |
) |
|
|
|
||||
Environmental Remediation Expense |
|
$ |
52 |
|
|
|
|
|
$ |
327 |
|
|
|
|
|
$ |
461 |
|
|
|
|
|
$ |
630 |
|
|
|
|
||||
Total Pre-Tax Adjustments |
|
$ |
(835 |
) |
|
|
|
|
$ |
1,162 |
|
|
|
|
|
$ |
(460 |
) |
|
|
|
|
$ |
(4,206 |
) |
|
|
|
||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||
Cumulative Tax Effect on Adjustments |
|
$ |
208 |
|
|
|
|
|
$ |
(279 |
) |
|
|
|
|
$ |
110 |
|
|
|
|
|
$ |
1,007 |
|
|
|
|
||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||
After-Tax Adjustments |
|
$ |
(627 |
) |
|
$ |
(0.02 |
) |
|
$ |
883 |
|
|
$ |
0.04 |
|
|
$ |
(350 |
) |
|
$ |
(0.01 |
) |
|
$ |
(3,199 |
) |
|
$ |
(0.14 |
) |
10
Table III
Deferred Compensation Plans
The full effect of the deferred compensation plans on quarterly pre-tax income was $0.9 million of income versus $0.7 million of expense in the prior year. The year-to-date impact was $1.0 million of income versus $4.5 million of income in the prior year. The accounting for the deferred compensation plans results in operating income when the price of Stepan Company common stock or mutual funds held in the plans fall and expense when they rise. The Company also recognizes the change in value of mutual funds as investment income or loss. The quarter end market prices of Company common stock were as follows:
|
|
2023 |
|
|
2022 |
|
||||||||||||||||||||||
|
|
12/31 |
|
9/30 |
|
6/30 |
|
|
3/31 |
|
|
12/31 |
|
|
9/30 |
|
|
6/30 |
|
|
3/31 |
|
||||||
Stepan Company |
|
N/A |
|
N/A |
|
$ |
95.56 |
|
|
$ |
103.03 |
|
|
$ |
106.46 |
|
|
$ |
93.67 |
|
|
$ |
101.35 |
|
|
$ |
98.81 |
|
The deferred compensation income statement impact is summarized below:
|
|
Three Months Ended |
|
|
Six Months Ended |
|
||||||||||
($ in thousands) |
|
2023 |
|
|
2022 |
|
|
2023 |
|
|
2022 |
|
||||
Deferred Compensation |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Operating Income (Expense) |
|
$ |
(743 |
) |
|
$ |
3,406 |
|
|
$ |
(2,245 |
) |
|
$ |
10,907 |
|
Other, net – Mutual Fund Gain (Loss) |
|
|
1,614 |
|
|
|
(4,087 |
) |
|
|
3,254 |
|
|
|
(6,393 |
) |
Total Pretax |
|
$ |
871 |
|
|
$ |
(681 |
) |
|
$ |
1,009 |
|
|
$ |
4,514 |
|
Total After Tax |
|
$ |
653 |
|
|
$ |
(518 |
) |
|
$ |
757 |
|
|
$ |
3,431 |
|
11
Table IV
Effects of Foreign Currency Translation
The Company’s foreign subsidiaries transact business and report financial results in their respective local currencies. As a result, foreign subsidiary income statements are translated into U.S. dollars at average foreign exchange rates appropriate for the reporting period. Because foreign currency exchange rates fluctuate against the U.S. dollar over time, foreign currency translation affects period-to-period comparisons of financial statement items (i.e., because foreign exchange rates fluctuate, similar period-to-period local currency results for a foreign subsidiary may translate into different U.S. dollar results). Below is a table that presents the impact that foreign currency translation had on the changes in consolidated net sales and various income statement line items for the three and six month periods ending June 30, 2023 as compared to 2022:
($ in millions) |
|
Three Months Ended |
|
|
Decrease |
|
|
Change Due to Foreign Currency |
|
|
Six Months Ended |
|
|
Decrease |
|
|
Change Due to Foreign Currency |
|
||||||||||||||
|
|
2023 |
|
|
2022 |
|
|
|
|
|
|
|
|
2023 |
|
|
2022 |
|
|
|
|
|
|
|
||||||||
Net Sales |
|
$ |
579.98 |
|
|
$ |
751.63 |
|
|
$ |
(171.60 |
) |
|
$ |
4.40 |
|
|
$ |
1,231.41 |
|
|
$ |
1,426.91 |
|
|
$ |
(195.50 |
) |
|
$ |
(8.05 |
) |
Gross Profit |
|
|
66.4 |
|
|
|
131.6 |
|
|
|
(65.2 |
) |
|
|
0.5 |
|
|
|
140.0 |
|
|
|
240.8 |
|
|
|
(100.8 |
) |
|
|
(1.1 |
) |
Operating Income |
|
|
17.8 |
|
|
|
77.6 |
|
|
|
(59.8 |
) |
|
|
0.3 |
|
|
|
38.9 |
|
|
|
141.0 |
|
|
|
(102.1 |
) |
|
|
(0.8 |
) |
Pretax Income |
|
|
16.3 |
|
|
|
69.5 |
|
|
|
(53.2 |
) |
|
|
0.2 |
|
|
|
36.2 |
|
|
|
128.9 |
|
|
|
(92.7 |
) |
|
|
(0.9 |
) |
12
Table V
Stepan Company
Consolidated Balance Sheets
June 30, 2023 and December 31, 2022
|
|
June 30, 2023 |
|
|
December 31, 2022 |
|
||
ASSETS |
|
|
|
|
|
|
||
Current Assets |
|
$ |
938,722 |
|
|
$ |
1,044,802 |
|
Property, Plant & Equipment, Net |
|
|
1,165,784 |
|
|
|
1,073,297 |
|
Other Assets |
|
|
326,312 |
|
|
|
315,073 |
|
Total Assets |
|
$ |
2,430,818 |
|
|
$ |
2,433,172 |
|
LIABILITIES AND STOCKHOLDERS’ EQUITY |
|
|
|
|
|
|
||
Current Liabilities |
|
$ |
642,037 |
|
|
$ |
670,649 |
|
Deferred Income Taxes |
|
|
9,071 |
|
|
|
10,179 |
|
Long-term Debt |
|
|
438,269 |
|
|
|
455,029 |
|
Other Non-current Liabilities |
|
|
126,344 |
|
|
|
131,250 |
|
Total Stepan Company Stockholders’ Equity |
|
|
1,215,097 |
|
|
|
1,166,065 |
|
Total Liabilities and Stockholders’ Equity |
|
$ |
2,430,818 |
|
|
$ |
2,433,172 |
|
13
Table VI
Reconciliations of Non-GAAP EBITDA and Adjusted EBITDA to Operating Income
|
|
Three Months Ended |
|
|||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||
($ in millions) |
|
Surfactants |
|
|
Polymers |
|
|
Specialty Products |
|
|
Unallocated Corporate |
|
|
Consolidated |
|
|||||
Operating Income |
|
$ |
15.1 |
|
|
$ |
16.3 |
|
|
$ |
3.8 |
|
|
$ |
(17.4 |
) |
|
$ |
17.8 |
|
Depreciation and Amortization |
|
$ |
16.0 |
|
|
$ |
8.3 |
|
|
$ |
1.4 |
|
|
$ |
0.8 |
|
|
$ |
26.5 |
|
Other, Net Income (Expense) |
|
$ |
- |
|
|
$ |
- |
|
|
$ |
- |
|
|
$ |
2.4 |
|
|
$ |
2.4 |
|
EBITDA |
|
$ |
31.1 |
|
|
$ |
24.6 |
|
|
$ |
5.2 |
|
|
$ |
(14.2 |
) |
|
$ |
46.7 |
|
Deferred Compensation |
|
$ |
- |
|
|
$ |
- |
|
|
$ |
- |
|
|
$ |
(0.9 |
) |
|
$ |
(0.9 |
) |
Cash Settled SARs |
|
$ |
(0.1 |
) |
|
$ |
- |
|
|
$ |
- |
|
|
$ |
- |
|
|
$ |
(0.1 |
) |
Business Restructuring |
|
$ |
- |
|
|
$ |
- |
|
|
$ |
- |
|
|
$ |
- |
|
|
$ |
- |
|
Environmental Remediation |
|
$ |
- |
|
|
$ |
- |
|
|
$ |
- |
|
|
$ |
0.1 |
|
|
$ |
0.1 |
|
Adjusted EBITDA |
|
$ |
31.0 |
|
|
$ |
24.6 |
|
|
$ |
5.2 |
|
|
$ |
(15.0 |
) |
|
$ |
45.8 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||
|
|
Three Months Ended |
|
|||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||
($ in millions) |
|
Surfactants |
|
|
Polymers |
|
|
Specialty Products |
|
|
Unallocated Corporate |
|
|
Consolidated |
|
|||||
Operating Income |
|
$ |
48.2 |
|
|
$ |
33.9 |
|
|
$ |
9.9 |
|
|
$ |
(14.4 |
) |
|
$ |
77.6 |
|
Depreciation and Amortization |
|
$ |
13.4 |
|
|
$ |
7.9 |
|
|
$ |
1.5 |
|
|
$ |
0.5 |
|
|
$ |
23.3 |
|
Other, Net Income (Expense) |
|
$ |
- |
|
|
$ |
- |
|
|
$ |
- |
|
|
$ |
(5.4 |
) |
|
$ |
(5.4 |
) |
EBITDA |
|
$ |
61.6 |
|
|
$ |
41.8 |
|
|
$ |
11.4 |
|
|
$ |
(19.3 |
) |
|
$ |
95.5 |
|
Deferred Compensation |
|
$ |
- |
|
|
$ |
- |
|
|
$ |
- |
|
|
$ |
0.7 |
|
|
$ |
0.7 |
|
Cash Settled SARs |
|
$ |
0.1 |
|
|
$ |
- |
|
|
$ |
- |
|
|
$ |
- |
|
|
$ |
0.1 |
|
Business Restructuring |
|
$ |
- |
|
|
$ |
- |
|
|
$ |
- |
|
|
$ |
0.1 |
|
|
$ |
0.1 |
|
Environmental Remediation |
|
$ |
- |
|
|
$ |
- |
|
|
$ |
- |
|
|
$ |
0.3 |
|
|
$ |
0.3 |
|
Adjusted EBITDA |
|
$ |
61.7 |
|
|
$ |
41.8 |
|
|
$ |
11.4 |
|
|
$ |
(18.2 |
) |
|
$ |
96.7 |
|
|
|
Six Months Ended |
|
|||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||
($ in millions) |
|
Surfactants |
|
|
Polymers |
|
|
Specialty Products |
|
|
Unallocated Corporate |
|
|
Consolidated |
|
|||||
Operating Income |
|
$ |
42.2 |
|
|
$ |
26.3 |
|
|
$ |
6.3 |
|
|
$ |
(35.9 |
) |
|
$ |
38.9 |
|
Depreciation and Amortization |
|
$ |
31.3 |
|
|
$ |
16.6 |
|
|
$ |
2.8 |
|
|
$ |
1.3 |
|
|
$ |
52.0 |
|
Other, Net Income (Expense) |
|
$ |
- |
|
|
$ |
- |
|
|
$ |
- |
|
|
$ |
4.0 |
|
|
$ |
4.0 |
|
EBITDA |
|
$ |
73.5 |
|
|
$ |
42.9 |
|
|
$ |
9.1 |
|
|
$ |
(30.6 |
) |
|
$ |
94.9 |
|
Deferred Compensation |
|
$ |
- |
|
|
$ |
- |
|
|
$ |
- |
|
|
$ |
(1.0 |
) |
|
$ |
(1.0 |
) |
Cash Settled SARs |
|
$ |
(0.1 |
) |
|
$ |
- |
|
|
$ |
- |
|
|
$ |
- |
|
|
$ |
(0.1 |
) |
Business Restructuring |
|
$ |
- |
|
|
$ |
- |
|
|
$ |
- |
|
|
$ |
0.2 |
|
|
$ |
0.2 |
|
Environmental Remediation |
|
$ |
- |
|
|
$ |
- |
|
|
$ |
- |
|
|
$ |
0.5 |
|
|
$ |
0.5 |
|
Adjusted EBITDA |
|
$ |
73.4 |
|
|
$ |
42.9 |
|
|
$ |
9.1 |
|
|
$ |
(30.9 |
) |
|
$ |
94.5 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||
|
|
Six Months Ended |
|
|||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||
($ in millions) |
|
Surfactants |
|
|
Polymers |
|
|
Specialty Products |
|
|
Unallocated Corporate |
|
|
Consolidated |
|
|||||
Operating Income |
|
$ |
102.0 |
|
|
$ |
48.0 |
|
|
$ |
13.6 |
|
|
$ |
(22.6 |
) |
|
$ |
141.0 |
|
Depreciation and Amortization |
|
$ |
26.6 |
|
|
$ |
15.6 |
|
|
$ |
2.9 |
|
|
$ |
1.1 |
|
|
$ |
46.2 |
|
Other, Net Income (Expense) |
|
$ |
- |
|
|
$ |
- |
|
|
$ |
- |
|
|
$ |
(7.0 |
) |
|
$ |
(7.0 |
) |
EBITDA |
|
$ |
128.6 |
|
|
$ |
63.6 |
|
|
$ |
16.5 |
|
|
$ |
(28.5 |
) |
|
$ |
180.2 |
|
Deferred Compensation |
|
|
|
|
|
|
|
|
|
|
$ |
(4.5 |
) |
|
$ |
(4.5 |
) |
|||
Cash Settled SARs |
|
$ |
(0.2 |
) |
|
$ |
(0.1 |
) |
|
$ |
- |
|
|
$ |
(0.1 |
) |
|
$ |
(0.4 |
) |
Business Restructuring |
|
|
|
|
|
|
|
|
|
|
$ |
0.1 |
|
|
$ |
0.1 |
|
|||
Environmental Remediation |
|
|
|
|
|
|
|
|
|
|
$ |
0.6 |
|
|
$ |
0.6 |
|
|||
Adjusted EBITDA |
|
$ |
128.4 |
|
|
$ |
63.5 |
|
|
$ |
16.5 |
|
|
$ |
(32.4 |
) |
|
$ |
176.0 |
|
14
